Jochen Eimer

• Advised an Austrian listed biotech company on the negotiation of a clinical supply agreement with a global biopharma company ancillary to an existing collaboration and licence agreement.*
• Advised an Austrian listed biotech company on a global licence agreement with a Swiss university.*
• Advised a German cell therapy company on establishing an intra-group master services and supply agreement and other related agreements.*
• Advised a Swiss biotech company on a collaboration and licence agreement with a Benelux biotech company involving the algorithm-based identification and selection of patient-individual tumour-specific drug targets.*
• Advised a Swiss biotech company on a clinical trial collaboration agreement with a Japanese IT company involving the algorithm-based identification and selection of patient-individual tumour-specific drug targets.*
• Advised a German listed biotech company on the global restructuring of its manufacturing and supply relationships, including the negotiation of a commercial manufacturing and supply agreement with its API supplier, as well as corresponding supply agreements with its third-party licensees.*
• Advised a German nutraceutical company on its corporate reorganisation, as well as on a global manufacturing and supply agreement with a US customer.*
• Advised a Polish biotech company on the negotiation of a research collaboration and option agreement, as well as a separate research collaboration and licence agreement with a leading German pharma company.*
• Advised a Swiss biotech company on a licence and collaboration agreement with an international pharmaceutical company for China and other regions worldwide.*
• Advised a German listed biotech company on the negotiation of a global licence and co-development agreement for its lead compound and various ancillary agreements, including a development supply agreement and a manufacture licence and tech transfer agreement.*
• Advised an Australian pharma company on the regional amendment of its existing supply agreement with a global pharma company to include certain European territories.*
• Advised an Austrian listed biotech company on a research collaboration and licence agreement with a US-based cancer medicine company with respect to a certain preclinical discovery programme.*
• Advised an Austrian listed biotech company on a research collaboration and licence agreement with a global biopharma company.*
• Advised a leading German pharma company on a cooperation agreement with a world-leading diagnostics company in the area of companion diagnostics.*
• Advised a German pharma company on a global licence agreement with an Italian pharma company.*
• Advised a German biotech company on a collaboration with a German research institute.*
• Advised a Polish biotech company on a global licence agreement with an Italian pharma company.*
• Advised a German biotech company on a licence and cooperation agreement with a world-leading diagnostics company in the area of companion diagnostics.*
• Advised a Polish biotech company on the launch of a new biotech company established together with a venture capital firm.*
• Advised a leading gene therapy company on an exclusive strategic collaboration with a global biopharmaceutical company.*

* Matter handled prior to joining the firm.